E-viri
Recenzirano
Odprti dostop
-
Messner, Christoph B.; Demichev, Vadim; Wendisch, Daniel; Michalick, Laura; White, Matthew; Freiwald, Anja; Textoris-Taube, Kathrin; Vernardis, Spyros I.; Egger, Anna-Sophia; Kreidl, Marco; Ludwig, Daniela; Kilian, Christiane; Agostini, Federica; Zelezniak, Aleksej; Thibeault, Charlotte; Pfeiffer, Moritz; Hippenstiel, Stefan; Hocke, Andreas; von Kalle, Christof; Campbell, Archie; Hayward, Caroline; Porteous, David J.; Marioni, Riccardo E.; Langenberg, Claudia; Lilley, Kathryn S.; Kuebler, Wolfgang M.; Mülleder, Michael; Drosten, Christian; Suttorp, Norbert; Witzenrath, Martin; Kurth, Florian; Sander, Leif Erik; Ralser, Markus
Cell systems, 07/2020, Letnik: 11, Številka: 1Journal Article
The COVID-19 pandemic is an unprecedented global challenge, and point-of-care diagnostic classifiers are urgently required. Here, we present a platform for ultra-high-throughput serum and plasma proteomics that builds on ISO13485 standardization to facilitate simple implementation in regulated clinical laboratories. Our low-cost workflow handles up to 180 samples per day, enables high precision quantification, and reduces batch effects for large-scale and longitudinal studies. We use our platform on samples collected from a cohort of early hospitalized cases of the SARS-CoV-2 pandemic and identify 27 potential biomarkers that are differentially expressed depending on the WHO severity grade of COVID-19. They include complement factors, the coagulation system, inflammation modulators, and pro-inflammatory factors upstream and downstream of interleukin 6. All protocols and software for implementing our approach are freely available. In total, this work supports the development of routine proteomic assays to aid clinical decision making and generate hypotheses about potential COVID-19 therapeutic targets. Display omitted •A standardized, ultra-high-throughput clinical platform for serum and plasma proteomics•Platform enables high precision quantification of 180 human proteomes per day at low cost•27 biomarkers are differentially expressed between WHO severity grades for COVID-19•Biomarkers include proteins not previously associated with COVID-19 infection Messner et al. present a standardized, low-cost, ultra-high-throughput platform for serum and plasma proteomics designed for clinical use and apply it to a cohort of hospitalized COVID-19 patients. They identify 27 potential biomarkers that are differentially expressed depending on the WHO severity grade of COVID-19.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.